NR (Nicotinamide Riboside) is the most clinically-studied NAD+ precursor. The NIAGEN form has 20+ published human trials confirming safe NAD+ elevation.
NR safely and dose-dependently increased blood NAD+ levels in humans, first definitive proof of human bioavailability of an NAD+ precursor.
NR safely elevated NAD+ and reduced systolic blood pressure and arterial stiffness in adults at risk for cardiovascular disease.
NIAGEN (the patented NR form) demonstrated a clean safety profile across trials, with no serious adverse events attributable to supplementation.
We prioritize randomised controlled trials and meta-analyses over single observational studies. Animal and in-vitro data are listed as "mechanistic", they suggest direction, not human effect size.
We don't cherry-pick favourable studies, omit conflicting evidence, or cite industry-funded trials without flagging the conflict of interest where known.
The research is one thing, what to take, at what dose, paired with what, is another. We compose stacks that turn the evidence into a daily routine.
Studies referenced are real published research. Summaries are paraphrased for accessibility, for exact methods and full text, click through to PubMed. Educational use only, not medical advice. Consult a qualified clinician before starting any new supplement.